MOLN biotech catalysts & pipeline

MOLECULAR PARTNERS AG · Data as of 2026-10-25

Upcoming catalysts

MP0712 — Clinical data readout

2026

• DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027

Source filing

MP0726 — Initial data

H2 2026

The Company communicated in July 2026 that it intends to advance MSLN-targeting MP0726, its second RDT program, to first-in-human imaging in H2 2026.

Source filing

MP0317 — Interim data

2027

Data update expected in 2027, with trial completion in 2028

Source filing

MP0712 — Full data

2027

• DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027

Source filing

CD70-targeting radiopharmaceutical therapy — Conference presentation

H2 2026

The Company intends to present supporting pre-clinical data at a scientific congress in H2 2026.

Source filing

MP0317 — Conference presentation

Oct 23–Oct 27

Trial-in-progress poster to be presented at ESMO 2026 in October

Source filing

MP0632 — Conference presentation

Nov 4–Nov 8

The Company will present additional pre-clinical data on MP0632 at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2026.

Source filing

Explore the free biotech catalyst calendar